MTOR and breast cancer: Furthermore, treatment of breast cancer cells with JPH203, a tyrosine analog and selective LAT1 inhibitor, limited the amount of leucine, and also tyrosine, that could maintain protein production or enter the TCA cycle, proving to be beneficial in combination with other mTOR inhibitors and/or endocrine therapies for breast cancer treatment [108].